Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 101 - 125 of 1616 in total
PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others.
Investigational
Matched Name: … PF-05175157
Matched Description: … PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes …
PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.
Investigational
Matched Name: … PF-03654746
Matched Description: … PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome …
PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis.
Investigational
Matched Name: … PF-03654764
Matched Description: … PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis. …
Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.
Investigational
Matched Name: … Pf-04531083
Matched Description: … Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain. …
PF-00217830 has been used in trials studying the treatment of Schizophrenia.
Investigational
Matched Name: … PF-00217830
Matched Description: … PF-00217830 has been used in trials studying the treatment of Schizophrenia. …
PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
Investigational
Matched Name: … PF-05180999
Matched Description: … of a Modified-Release Formulation of PF-05180999). ... PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability …
AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).
Investigational
Matched Name: … AK106-001616
Matched Description: … AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients …
Investigational
Matched Name: … EP-0042
Matched Salts name: … EP-0042 fumarate …
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
Matched Name: … AGS-005
Matched Description: … AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics …
Atu027 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Matched Name: … ATU-027
Investigational
Matched Name: … ANX-005
Investigational
Matched Name: … ACP-015
Investigational
Matched Synonyms: … NBL-015 (ANTI-CLAUDIN18.2 MAB) …
Matched Name: … NBL-015
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Matched Name: … CALY-002
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Name: … Sirna-027
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth …
Experimental
Withdrawn
Matched Synonyms: … BMN 044 ... BMN-044
Matched Name: … BMN-044
VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.
Investigational
Matched Synonyms: … VAD 044 ... VAD-044
Matched Name: … VAD-044
Matched Description: … VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. …
ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).
Investigational
Matched Name: … ELX-02
Matched Description: … ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult …
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Name: … CB-010
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
Investigational
Matched Synonyms: … M 032
Matched Name: … M-032
DR-01 is a monoclonal antibody directed against human CD94.
Investigational
Matched Name: … DR-01
Matched Description: … DR-01 is a monoclonal antibody directed against human CD94. …
NNC0114-0006 is an anti-interleukin 21 monoclonal antibody
Investigational
Matched Name: … NNC0114-0006
Matched Description: … NNC0114-0006 is an anti-interleukin 21 monoclonal antibody …
Investigational
Matched Synonyms: … PTR-01
Matched Name: … PTR-01
Investigational
Matched Name: … SD-0006
OTX008 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Name: … OTX-008
Displaying drugs 101 - 125 of 1616 in total